Company profile: Cernostics
1.1 - Company Overview
Company description
- Provider of molecular diagnostic tests for cancer, leveraging its patent-protected TissueCypher platform. TissueCypher is a laboratory-developed test that analyzes tissue from Barrett's esophagus biopsies to provide a patient's five-year risk of progression to high-grade dysplasia or esophageal adenocarcinoma.
Products and services
- TissueCypher: A laboratory-developed test that analyzes tissue from Barrett's esophagus biopsies to deliver a patient's five-year risk of progression to high-grade dysplasia or esophageal adenocarcinoma
- TissueCypher Technology Platform: A patent-protected technology platform named TissueCypher utilized by Cernostics in developing new molecular diagnostic tests for the fight against cancer
- Molecular Diagnostic Test Development: A systems-level program that architects new molecular diagnostic tests for the fight against cancer, considering tumors as composed of multiple cell types beyond tumor cells
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cernostics
Proteovant Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology solutions utilizing protein degradation research to develop medicines for diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Proteovant Therapeutics company profile →
Celleron Therapeutics
HQ: United Kingdom
Website
- Description: Provider of oncology therapeutics and biomarker-driven precision medicine, developing epigenetic biomarkers to match drugs to responsive disease. Pipeline includes Zabadinostat, an immune modulator with clinical activity in colorectal cancer, liver cancer, and lymphoma; PCV-001, a preclinical precision cancer vaccine; and AT-101, an in-house PRMT5 inhibitor in clinical planning.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Celleron Therapeutics company profile →
LadRx
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics leveraging LADR (Linker Activated Drug Release) technology to bind anti-cancer molecules to albumin and release cytotoxic payloads at tumors, enabling higher doses with minimized off-target toxicity. Portfolio includes Aldoxorubicin, next-generation LADR-7, and Arimoclomol to amplify heat-shock proteins against protein misfolding, aggregation, and lysosomal dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LadRx company profile →
Lightpoint Medical
HQ: United Kingdom
Website
- Description: Provider of intraoperative imaging technology for real-time cancer detection during surgery, including Cerenkov Luminescence Imaging (CLI) to reduce recurrence and reoperation; offers SENSEI®, a miniature gamma probe for minimally-invasive and robot-assisted procedures to detect radiation and guide surgeons.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lightpoint Medical company profile →
PCI Biotech
HQ: Norway
Website
- Description: Provider of photochemical drug delivery technologies for cancer therapy, focusing on photochemical internalisation (PCI) to enhance intracellular delivery of therapeutic compounds for novel cancer treatments, and photochemical lysis (PCL) to improve viral vector manufacturing through light-triggered cell lysis that increases yield and reduces impurities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PCI Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cernostics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cernostics
2.2 - Growth funds investing in similar companies to Cernostics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cernostics
4.2 - Public trading comparable groups for Cernostics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →